Ruzzi, Francesca; Riccardo, Federica; Conti, Laura; Tarone, Lidia; Semprini, Maria Sofia; Bolli, Elisabetta; Barutello, Giuseppina; Quaglino, Elena; Lollini, Pier-Luigi; Cavallo, Federica, Cancer vaccines: Target antigens, vaccine platforms and preclinical models, «MOLECULAR ASPECTS OF MEDICINE», 2025, 101, Article number: 101324, pp. 1 - 17 [articolo]
Pasello M.; Laginestra M.A.; Manara M.C.; Landuzzi L.; Ruzzi F.; Maioli M.; Pellegrini E.; De Feo A.; Lollini P.-L.; Scotlandi K., CD99 contributes to the EWS::FLI1 transcriptome by specifically affecting FOXM1-targets involved in the G2/M cell cycle phase, thus influencing the Ewing sarcoma genetic landscape, «JOURNAL OF CELL COMMUNICATION AND SIGNALING», 2024, Online ahead of print, Article number: e12047, pp. 1 - 15 [articolo]Open Access
Di Federico, Alessandro; Angelicola, Stefania; Frascino, Mariateresa; Siracusa, Irene; Bisanti, Beatrice; Ruzzi, Francesca; Semprini, Maria Sofia; De Jonge, Hugo; De Giglio, Andrea; Sperandi, Francesca; Brocchi, Stefano; Melotti, Barbara; Giunchi, Francesca; Gruppioni, Elisa; Altimari, Annalisa; Lollini, Pier-Luigi; Ardizzoni, Andrea; Palladini, Arianna; Gelsomino, Francesco, Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations, «JCO PRECISION ONCOLOGY», 2024, 8, Article number: 240, pp. 1 - 9 [articolo]
Manara, Maria Cristina; Manferdini, Cristina; Cristalli, Camilla; Carrabotta, Marianna; Santi, Spartaco; De Feo, Alessandra; Caldoni, Giulia; Pasello, Michela; Landuzzi, Lorena; Lollini, Pier-Luigi; Salamanna, Francesca; Dominici, Sabrina; Fiori, Valentina; Magnani, Mauro; Lisignoli, Gina; Scotlandi, Katia, Engagement of CD99 activates distinct programs in Ewing sarcoma and macrophages, «CANCER IMMUNOLOGY RESEARCH», 2024, 12, pp. 1 - 14 [articolo]Open Access
Ruzzi F.; Semprini M.S.; Scalambra L.; Angelicola S.; Cappello C.; Pittino O.M.; Nanni P.; Palladini A.; Lollini P.L., Functional evaluation of circulating anti-cancer antibodies with a 3D tumor cell growth inhibition assay, «METHODS IN CELL BIOLOGY», 2024, 190, pp. 75 - 86 [articolo]
Lorena Landuzzi, Francesca Ruzzi, Evelin Pellegrini, Pier-Luigi Lollini, Katia Scotlandi, Maria Cristina Manara, IL-1 Family Members in Bone Sarcomas, «CELLS», 2024, 13, Article number: 233, pp. 1 - 16 [articolo]Open Access
Francesca Ruzzi, Chiara Cappello, Maria Sofia Semprini, Laura Scalambra, Stefania Angelicola,
Olga Maria Pittino, Lorena Landuzzi, Arianna Palladini, Patrizia Nanni, Pier-Luigi Lollini, Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes?, «CELL COMMUNICATION AND SIGNALING», 2024, 22, Article number: 248, pp. 1 - 10 [articolo]Open Access
Rothe R.; Xu Y.; Wodtke J.; Brandt F.; Meister S.; Laube M.; Lollini P.-L.; Zhang Y.; Pietzsch J.; Hauser S., Programmable Release of Chemotherapeutics from Ferrocene-Based Injectable Hydrogels Slows Melanoma Growth, «ADVANCED HEALTHCARE MATERIALS», 2024, 2024, Article number: 2400765, pp. 1 - 19 [articolo]
Setola, Elisabetta; Benini, S; Righi, A; Gamberi, G; Carretta, E; Ferrari, C; Avnet, S; Palmerini, E; Magagnoli, G; Gambarotti, M; Lollini, P L; Cesari, M; Cocchi, S; Paioli, A; Longhi, A; Scotlandi, K; Laginestra, M A; Donati, D M; Baldini, N; Ibrahim, T, IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience, «BMC CANCER», 2023, 23, Article number: 907, pp. 1 - 12 [articolo]Open Access
Landuzzi L.; Manara M.C.; Pazzaglia L.; Lollini P.L.; Scotlandi K., Innovative Breakthroughs for the Treatment of Advanced and Metastatic Synovial Sarcoma, «CANCERS», 2023, 15, Article number: 3887, pp. 1 - 20 [articolo]Open Access
Ruzzi, F; Palladini, A; Clemmensen, S; Strobaek, A; Buijs, N; Domeyer, T; Dorosz, J; Soroka, V; Grzadziela, D; Rasmussen, CJ; Nielsen, IB; Soegaard, M; Semprini, MS; Scalambra, L; Angelicola, S; Landuzzi, L; Lollini, PL; Thorn, M, Preclinical activity of ES2B-C001, a human candidate HER-2 virus-like particle (VLP) vaccine, against mammary carcinoma onset and metastasis, «CANCER RESEARCH», 2023, 83, pp. 687 - 687 [abstract]
Lorena Landuzzi, Francesca Ruzzi, Pier-Luigi Lollini, Katia Scotlandi, Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational Research, «CANCERS», 2023, 15, Article number: 588, pp. 1 - 24 [articolo]Open Access
Ruzzi F.; Semprini M.S.; Scalambra L.; Palladini A.; Angelicola S.; Cappello C.; Pittino O.M.; Nanni P.; Lollini P.-L., Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy, «INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES», 2023, 24, Article number: 12963, pp. 1 - 21 [articolo]Open Access
Pasello, Michela; Giudice, Anna Maria; Cristalli, Camilla; Manara, Maria Cristina; Mancarella, Caterina; Parra, Alessandro; Serra, Massimo; Magagnoli, Giovanna; Cidre-Aranaz, Florencia; Grünewald, Thomas G P; Bini, Carla; Lollini, Pier-Luigi; Longhi, Alessandra; Donati, Davide Maria; Scotlandi, Katia, ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the IGF1R/AKT/MDM2 axis, «CELLULAR ONCOLOGY», 2022, 45, pp. 1237 - 1251 [articolo]Open Access
Ruzzi, Francesca; Angelicola, Stefania; Landuzzi, Lorena; Nironi, Elena; Semprini, Maria Sofia; Scalambra, Laura; Altimari, Annalisa; Gruppioni, Elisa; Fiorentino, Michelangelo; Giunchi, Francesca; Ferracin, Manuela; Astolfi, Annalisa; Indio, Valentina; Ardizzoni, Andrea; Gelsomino, Francesco; Nanni, Patrizia; Lollini, Pier-Luigi; Palladini, Arianna, ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC, «TRANSLATIONAL LUNG CANCER RESEARCH», 2022, 11, pp. 2216 - 2229 [articolo]Open Access
